TY  - JOUR
AU  - Straub, Manuela
AU  - Kupferschläger, Jürgen
AU  - Serna Higuita, Lina Maria
AU  - Weissinger, Matthias
AU  - Dittmann, Helmut
AU  - la Fougère, Christian
AU  - Fiz, Francesco
TI  - Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 9
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-01363
SP  - 1431-1438
PY  - 2023
N1  - 2023 Sep;64(9):1431-1438
AB  - 177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant prostate cancer (mCRPC). However, some patients progress under treatment. We hypothesized that the tracer kinetics within the metastases may influence the therapy effectiveness and tested this hypothesis by analyzing uptake parameters on 2 consecutive posttherapy SPECT/CT scans. Methods: mCRPC patients treated with 177Lu-PSMA-617 and with available posttherapy SPECT/CT imaging (24 and 48 h after the first treatment) were enrolled retrospectively. Volumes of interest were defined on lymph node metastasis (LNM) and bone metastasis (BM) on both SPECT/CT scans. The reduction of the percentage injected dose (
KW  - 177Lu-PSMA-617 (Other)
KW  - RLT (Other)
KW  - SPECT/CT (Other)
KW  - dual time point (Other)
KW  - mCRPC (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37414446
DO  - DOI:10.2967/jnumed.122.264770
UR  - https://inrepo02.dkfz.de/record/277409
ER  -